BenevolentAI today announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector.
Health technology and clinical wearables are hot topics in the healthcare and pharmaceutical industries. They are creating waves of excitement and talking points for debate, while also topping many of the healthcare trends of this year.
One of the first studies to explore the effects of calorie restriction on humans showed that cutting caloric intake by 15% for 2 years slowed aging and metabolism and protected against age-related disease. The study, which will appear March 22 in the journal Cell Metabolism, found that calorie restriction decreased systemic oxidative stress, which has been tied to age-related neurological conditions such as Alzheimer's and Parkinson's diseases, as well as cancer, diabetes, and others.
A wearable device, developed by researchers at the GI Innovation Group out of the University of California San Diego, can track electrical activity in the stomach over a 24-hour period. The device works similarly to how an ECG would work for the heart, but instead it monitors the electrical activities of gastrointestinal tract.
A new generation of brain scanner, that can be worn like a helmet allowing patients to move naturally whilst being scanned, has been developed by researchers at the Sir Peter Mansfield Imaging Centre, University of Nottingham and the Wellcome Centre for Human Neuroimaging, UCL. It is part of a five-year Wellcome funded project which has the potential to revolutionize the world of human brain imaging.
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhibitor of RIPK1 in a Phase 1 clinical trial in healthy volunteers and achieved proof of concept of its large molecule blood-brain barrier delivery platform technology in nonhuman primates.
As brain cells age, they lose their ability to perform basic functions, often leading to dementia and other neurodegenerative disorders. But what’s behind this decline, and can it be stopped? Two new studies out this week uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.
As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
Boston-based startup Pear Therapeutics will link with Novartis to develop prescription-strength digital interventions for schizophrenia and multiple sclerosis (MS).
The UK Government has announced plans to increase prescription charges by 20p, or 2.3%, to a record £8.80, effective 1 April.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.